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Abstract
Objectives
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy
worldwide. Main HNSCC risk factors are tobacco, alcohol, and high-risk human papillomavi-
rus (HPV). HPV+ oropharyngeal squamous cell cancer (OPSCC) usually have different eti-
ology, increasing incidence and often show an improved survival when compared to HPV-
negative cases. The objective of the current study was to retrospectively examine the influ-
ence of HPV on the survival of OPSCC patients in a non-Western population setting.
Materials and methods
We determined the presence of HPV DNA and/or RNA in 99 formalin-fixed paraffin embed-
ded (FFPE) tissue samples of OPSCC patients treated between 2002 and 2015. Patients
were compared based on laboratory, demographic, clinical, life style characteristics and
survival.
Results
HPV RNA was found in 29.3% cases. However, groups based on HPV data (either RNA,
DNA or retrospectively collected p16 staining) did not show significant differences. Overall,
5-year survival was 30% with minimal influence of the HPV positivity.
Conclusions
The HPV influence on survival of OPSCC patients is not identical between populations prob-
ably due to other factors overshadowing the HPV effect. This should be taken into account
when treatment or policy decisions are made in each particular setting.







Citation: Bozˇinović K, Sabol I, Rakusˇić Z,
Jakovčević A, Sˇekerija M, Lukinović J, et al. (2019)
HPV-driven oropharyngeal squamous cell cancer in
Croatia — Demography and survival. PLoS ONE 14
(2): e0211577. https://doi.org/10.1371/journal.
pone.0211577
Editor: Scott M. Langevin, University of Cincinnati
College of Medicine, UNITED STATES
Received: October 3, 2018
Accepted: January 16, 2019
Published: February 1, 2019
Copyright: © 2019 Bozˇinović et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript.
Funding: This research has been supported by the
Croatian Science Foundation: Grant code IP-2013-
11-4758 (MG); Epigenetic changes in head and
neck squamous cell carcinoma - EpiC-HNSCC
(http://www.hrzz.hr/). The funder had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Introduction
Head-and-neck cancer (HNC) is a group of malignancies that most commonly arise from the
upper aerodigestive tract mucosa or lining of the head-and-neck regions [1]. It is the sixth
most common malignancy worldwide. Most HNCs (95%) develop from squamous cell epithe-
lia and are further characterized according to their primary site of origin. Most common sites
are oral cavity, oropharynx, pharynx, larynx, and sinonasal tract [2]. Globally, head-and-neck
squamous cell carcinoma (HNSCC) accounts for approximately 550,000 cases annually [3]
and in Croatia, there were estimated 750 cases in 2014 [4].
The main risk factors in general for developing HNSCC are tobacco, alcohol use and the
high-risk human papillomavirus (HPV) presence, with HPV-16 being found in majority of
HPV associated HNSCC [5]. High-risk HPV is capable of transforming infected cells into
cancerous ones by expressing oncoproteins E6 and E7, which bind, among others, to two of
the most important tumor suppressor genes, p53 and pRB, respectively [5]. Previous studies
have indicated that HNSCC, while very heterogeneous can be broadly divided into two groups:
HPV positive (HPV+) and HPV negative (HPV–). Indeed, HPV is responsible for 30–50%
HNSCC, with an increasing trend [5], found initially in the younger population of developed
countries, although recent evidence suggests that HPV+ OPSCC is also increasing in older
patients [6–8]. HPV+ HNSCC are often of oropharyngeal (OP) origin, with better prognosis
and rare p53 mutations, usually with low levels of tobacco and alcohol use [5,9–11]. On the
other hand, HPV–tumors are usually found in the elderly population with worse prognosis,
without preferable origin, with frequent p53 mutations and having long history of tobacco and
alcohol use. It is known that the incidence of HPV–HNSCC in the United States has been
declining, presumably due to a reduced prevalence of tobacco smoking [12]. Over the past few
decades, however, there has been a rise in HPV+ OPSCC [5,12–14]. In Croatia the trend
between 1988 and 2008 was showing decreasing overall incidence of HNSCC [15], with more
recent data corroborating the trend [4]. The proportion of HPV associated OPSCC is now
approximately 70% in the developing countries, which is a substantial increase from previous
rates [5,16]. Even though these two groups of HNSCC are etiologically different, the treatment
remains the same [17,18]. However, there are indications that the treatment could be opti-
mized for each group of patients, at least for HPV+ OPSCC patients [11,19]. Therefore, it is
crucial to get a better understanding of the disease and get detailed information on patients
including socio-epidemiological, clinical, biological and histopathological data.
In Croatia, only clinical guidelines for the treatment of laryngeal cancer currently exist, which is
only a subset of HNSCC, accounting for ~33% of HNSCC cases in the country, while there are no
guidelines for the treatment of cancers arising at other head-and-neck sites [15]. As HPV involve-
ment seems to drive the increase of OPSCC incidence in developed countries, establishing guidelines
for this cancer type could be of a future benefit to patients, but the baseline data for such guidelines
are scarce. Thus, in this study, we assessed archival formalin-fixed paraffin embedded (FFPE) tissue
of OPSCC patients for HPV presence (DNA) and activity (mRNA) to determine differences in
patient characteristics. Furthermore, medical records together with Croatian National Cancer Regis-
try data were evaluated to determine the influence of HPV on survival. The study objective was to
gain a better understanding of OPSCC in Croatian and similar non-Western populations.
Materials and methods
Patient samples
For this study, we collected a subset of available FFPE tumor tissue from 104 OPSCC patients
treated at the University Hospital Center Zagreb between 2002 and 2015. According to the
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International Classification of Disease (ICD-10), tumors included tonsils (C09), base of tongue
(C01), soft palate (C05.1), lateral wall (C10.2) and posterior wall of oropharynx (C10.3). One
patient had unspecified oropharynx tumor localization. Upon medical records reexamination,
five cases were excluded as the tumor originated from supraglotis/hypopharynx, thus 99 cases
were retained for analysis. The study was approved by the Bioethical Board of the Ruđer Bosˇ-
ković Institute (BEP-3748/2-2014) and the Ethical Board of the University Hospital Center
Zagreb (8.1-14/47-2, 02/21-JG). Since the study was retrospective and performed on anon-
ymized data from often deceased patients, the Ethical boards waived the necessity of obtaining
additional informed consent. Medical records and patient’s vital status, including previous p16
staining where available, were obtained from the hospital information system and the Croatian
National Cancer Registry [4] and contained relevant data collected during the establishment of
the initial diagnosis including pathological assessment. Original patient management treat-
ment decisions were not based upon HPV DNA or RNA testing but were made according to
tumor stage and overall patient state.
Data from the National Cancer Registry indicates that in the same period there were
approximately 1600 OPSCC patients diagnosed throughout Croatia with the same diagnosis
codes as used in the manuscript. However, of this number almost 500 were reported to the
Registry as C10.9 oropharynx, unspecified, which are underrepresented in our analyzed tis-
sues. The University Hospital Center Zagreb treated 403 oropharyngeal cancer patients during
this period. Thus, our sample represents approximately 7% of cancer patients in Croatia and
approximately 25% of patients treated at the hospital.
Malignancies were staged according to the 7th Edition of the American Joint Committee on
Cancer (AJCC) and the Union for International Cancer Control (UICC) TNM Classification
of Malignant tumors [20]. The pathologic classification was used and supplemented with the
clinical classification if missing. For the survival analyses, both 7th and 8th AJCC Edition stag-
ing guidelines [20,21] have been used and compared. Patient survival time in months was cal-
culated from the date of earliest diagnosis to registered time of death (all cause) or December
31st, 2017.
Nucleic acid isolation
Approximately 5–7 10 μm serial sections of each tissue block were obtained for DNA and
another 5–7 sections for RNA isolation. Precautions were taken to avoid sample cross-contam-
ination, including change of knife and meticulous cleaning of the microtome for each new
block as well as discarding top layers of each block that could potentially have been contami-
nated during storage. DNA was isolated with a NucleoSpin Tissue kit (Machery-Nagel), while
RNeasy FFPE Kit (Qiagen) was used for total RNA isolation of HPV+ samples. Isolation proce-
dures were performed according to the respective manufacturer’s protocol. Extracted DNA
and RNA were quantified using NanoPhotometer (Implen, Germany).
HPV DNA detection
Extracted DNA adequacy was further confirmed by PCR amplification of beta-actin gene (~99
bp) [22]. HPV DNA detection was performed using short primers suitable for FFPE tissue anal-
ysis, GP5/6 (~142bp amplicon) and SPF-10 (~65bp amplicon) previously described [23,24].
CaSki cell line DNA containing HPV-16 was used as positive control, while negative control
reactions contained all reagents except DNA. All standard precautions for avoiding cross con-
tamination were followed and reactions were prepared within a UV decontaminated laminar
flow hood. PCR products (10 μl) were visualized after 3% agarose gel electrophoresis. A sample
was considered as HPV DNA positive if consensus primers, either GP or SPF directed PCR was
HPV associated OPSCC survival
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positive and the results valid if beta-actin directed PCR (internal control) was successful. HPV
specific genotyping was not performed due to DNA degradation in FFPE samples.
E6/E6�I mRNA expression analyses
All HPV DNA positive samples were selected for RNA isolation and HPV-16 E6 mRNA detec-
tion. RNAse-free DNAse digestion was performed to further limit DNA contamination.
Briefly, 1 μg of RNA was reverse transcribed using QuantiTect Reverse Transcription kit (Qia-
gen) according to the manufacturer’s protocol. Most abundant splice variant of the E6 open
reading frame (E6�I) was detected by PCR [25] and the amplicons (~86 bp) visualized by a 3%
agarose electrophoresis. Suitability of cDNA for amplification was confirmed by beta-actin
PCR (~99 bp). CaSki cell line cDNA served as positive control, while negative control con-
tained all reagents except cDNA.
Immunohistochemistry
The p16 data was obtained from medical records of staining done by the CINtec p16INK4a
Histology Kit (mtm laboratories, Heidelberg, Germany) according to the manufacturer
instructions [26]. The staining was evaluated by the same pathologist (AJ) for all patients. The
overexpressed p16 (�70%) in tumour cells was considered as positive.
Statistical analyses
Based on HPV DNA and RNA testing results, samples were grouped in three distinct groups:
HPV DNA/RNA negative), HPV DNA positive and HPV RNA positive. Statistical analyses
were performed using R (v3.4.2) and MedCalc (v11.4 MedCalc Software, Ostend, Belgium).
Patient’s characteristics for specific variables (including gender, tumor localization, grade, TNM
and therapy) were compared between the groups using Test of Independence/Chi-Square and
correlation. Age at diagnosis was analyzed using T-test. For statistical purposes, missing data
was recoded as “Unknown” but retained to minimize possible selection bias. Survival data was
assessed in MedCalc using Kaplan-Meier analyses from which all non-primary tumors (n = 8)
and patients with unavailable survival data (n = 10) were excluded. When assessing tumor stag-
ing, patients were grouped to reduce the number of subgroups: for T classification “1–2” and
“2–3” groups were considered. For N classification, “0–1” and “2–3” groups were made, while
for tumor stages “I-II” and “III-IV” groups were considered irrespective of staging edition.
Patients self-reporting weekly or more common strong spirit use or daily other alcohol use were
grouped as heavy drinkers, while patients with self-reported occasional or limited alcohol use
were grouped as occasional drinkers. Influence of individual variables on survival were modeled
with Cox proportional hazards regression in univariate analysis for age, gender, HPV DNA pos-
itivity, HPV RNA positivity, p16 positivity, T classification, N classification, stage, grade, smok-
ing history and drinking history. Several multivariate Cox proportional hazards regression
models were created from selected significant or relevant variables (T/N classification) and
HPV groups. Several models were created from all entered variables without removal of non-
significant variables to enable the comparison of individual variable effects. However, the mod-
els including “Unknown” groups couldn’t be solved so for multivariate analysis, samples with
“Unknown” factors were removed. P values less than 0.05 were considered significant.
Results
From a total of 99 OPSCC patients, 59 (59.6%) were HPV DNA negative and 40 (40.4%) HPV
DNA positive, of which 11 (27.5%) were RNA negative, and 29 (72.5%) RNA positive.
HPV associated OPSCC survival
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Statistical analysis was done on those 3 subgroups: HPV DNA/RNA negative (N = 59), DNA
positive/RNA negative (N = 11), and DNA/RNA positive (N = 29). In addition, the tests were
also performed on the whole HPV DNA positive subgroup, including both RNA negative and
RNA positive samples (N = 40), but no additional statistical significance was found. Patient’s
characteristics are presented in Table 1. Male patients were predominant in all groups, and
account for 82.8% cases. Tonsil and base of tongue were the most common subsites, together
accounting for more than 86% of cases. There were no statistically significant differences
between the HPV groups in terms of age at the time of diagnosis (Fig 1) or gender. There were
14% never smokers and 13% never drinkers without significant differences between groups.
There was no correlation between HPV and p16 results with Pearson’s correlation coefficient
r = 0.14 for comparison with HPV RNA. The p16 positive staining was weakly statistically
associated with patient’s older age (t-test, P = 0.042) and with cancer higher grade (Mann-
Whitney, P = 0.017).
Table 1. Characteristics of the study population.
Variable HPV DNA and RNA positive
(N = 29)
HPV DNA positive and RNA negative
(n = 11)
HPV negative (n = 59) Total
(n = 99) a
Gender Male 22 (26.8%) 10 (12.2%) 50 (60.9%) 82
(82.8%)




Tonsil 17 (32.1%) 6 (11.3%) 30 (56.6%) 53
(53.5%)
Base of tongue 10 (30.3%) 5 (15.2%) 18 (54.6%) 33
(33.3%)
Soft palate 0 (0%) 0 (0%) 7 (100%) 7 (7.1%)
Lateral pharyngeal wall 2 (40%) 0 (0%) 3 (60%) 5 (5.1%)
Oropharynx
(unspecified)
0 (0%) 0 (0%) 1 (100%) 1 (1.0%)
Age group <45 2 (33.3%) 0 (0%) 4 (66. 7%) 6 (6.1%)
45–64 17 (27.9%) 9 (14.8%) 35 (57.4%) 61
(61.6%)
65+ 10 (31.3%) 2 (6.3%) 20 (62.5%) 32
(32.3%)
Median age 60 59 60 60
Smoking Active 4 (18.2%) 4 (18.2%) 14 (63.6%) 22
(22.2%)
Former 2 (20%) 0 (0%) 8 (80%) 10
(10.1%)
Does not smoke 6 (42.9%) 2 (14.3%) 6 (42.9%) 14
(14.1%)
Unknown 17 (32.1%) 5 (9.4%) 31 (58.5%) 53
(53.5%)
Drinking Heavy 1 (12.5%) 1 (12.5%) 6 (75%) 8 (8.1%)
Occasional 5 (20%) 4 (16%) 16 (64%) 25
(25.3%)
Does not drink 6 (46.6%) 1 (7.7%) 6 (46.2%) 13
(13.1%)
Unknown 17 (32.1%) 5 (9.4%) 31 (58.5%) 53
(53.5%)
atotal column percentages are calculated against the grand total
https://doi.org/10.1371/journal.pone.0211577.t001
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Clinical parameters are presented in Table 2; the majority of all patients with available data
were diagnosed with stage III or worse cancer (76.6%) according to the 7th edition AJCC
guidelines [20], and there was no significant difference between groups. However, according
to the 8th edition AJCC guidelines [21], the majority of RNA positive tumors were staged as
early and in this case the difference vs HPV–tumor group was significant (Chi-square test,
P<0.0001). Only 10% patients, for which data were available, were treated non-surgically. Pal-
liative therapy only was administered for 5 patients.
For survival analyses, 2 HPV RNA positive and 6 HPV RNA negative samples have been
excluded, due to samples originating from recurrent and not primary tumors. In addition, for
10 patients, follow-up or survival data couldn’t be obtained, and have been excluded. Thus, all-
cause mortality outcomes could be assessed for a total of 81 patients. Median follow-up (up to
December 31st, 2017) was 23.9 months. The overall survival at 5-years was 30.9%. Kaplan-
Meier survival curves for patient characteristics, clinical parameters, therapy and different
staging approaches are presented in Figs 2, 3 and 4, respectively. Combined risk level, taking
into account different patient aspects was aggregated and calculated as suggested by Ang et al
[27]. The original method included the grouping by HPV status, smoking and T and N stages
for HPV+ and HPV–cases, respectively. However, smoking was disregarded to retain more
cases, as smoking information was not available for all patients. Moreover, low and intermedi-
ate groups were combined as there were only 5 patients satisfying “low risk” criteria based on
the HPV RNA presence (Fig 4).
Patient characteristics (Fig 2) were not significantly (logrank test of Kaplan Myer survival
curves) affecting survival even though female gender, younger age and no history of smoking/
drinking were somewhat beneficial. Of clinical parameters (Fig 3), only T (P = 0.041) and N
(P = 0.021) classification significantly affected the overall outcome. On the other hand, HPV
+ and HPV–patients, regardless of the method of HPV detection (DNA, RNA or p16), had
very similar survival. The effect of therapy on survival (Fig 4) was also significant (P = 0.019).
In addition, both 7th (P = 0.017) and 8th (P = 0.001) editions of AJCC guidelines statistically
significantly affected survival. The analyses based on combined risk level (HPV status and T/N
Fig 1. Age at diagnosis in sample groups. DNA positive group consists of samples tested positive for DNA and
negative for RNA, while the RNA positive group tested positive for both DNA and RNA.
https://doi.org/10.1371/journal.pone.0211577.g001
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Table 2. Patient clinical characteristics.
Variable a HPV DNA and RNA positive
(N = 29)






T 1 4 (13.8%) 2 (18.2%) 5 (8.5%) 11 (11.1%)
2 6 (20.7%) 4 (36.4%) 19 (32.2%) 29 (29.3%)
3 6 (20.7%) 2 (18.2%) 8 (13.6%) 16 (16.2%)
4 3 (10.3%) 1 (9.1%) 13 (22.0%) 17 (17.2%)
Unknown 10 (34.5%) 2 (18.2%) 14 (23.7%) 26 (26.3%)
N 0 3 (10.3%) 3 (27.3%) 18 (30.5%) 24 (24.2%)
1 5 (17.2%) 3 (27.3%) 4 (6.8%) 12 (12.1%)
2 11 (37.9%) 3 (27.3%) 18 (30.5%) 32 (32.3%)
3 0 (0%) 0 (0%) 5 (8.5%) 5 (5.1%)
Unknown 10 (34.5%) 2 (18.2%) 14 (23.7%) 26 (26.3%)
7th edition staging guidelines Early 3 (10.3%) 2 (18.2%) 13 (22.0%) 18 (18.2%)
I 1 (3.5%) 1 (9.1%) 3 (5.1%) 5 (5.1%)
II 2 (6.9%) 1 (9.1%) 10 (16.9%) 13 (13.1%)
Late 16 (55.2%) 7 (63.6%) 36 (61.0%) 59 (59.6%)
III 6 (20.7%) 3 (27.3%) 7 (11.9%) 16 (16.2%)
IVa 10 (34.5%) 4 (36.4%) 19 (32.2%) 33 (33.3%)
IVb 0 (0%) 0 (0%) 5 (8.5%) 5 (5.1%)
IVc 0 (0%) 0 (0%) 5 (8.5%) 5 (5.1%)
Unknown 10 (34.5%) 2 (18.2%) 10 (16.9%) 22 (22.2%)
8th edition staging guidelines Early 16 (55.2%) 2 (18.2%) 13 (22.0%) 31 (31.3%)
I 7 (24.1%) 1 (9.1%) 3 (5.1%) 11 (11.1%)
II 9 (31.0%) 1 (9.1%) 10 (16.9%) 20 (20.2%)
Late 3 (10.3%) 7 (63.6%) 36 (61.0%) 46 (46.5%)
III 3 (10.3%) 3 (27.3%) 7 (11.9%) 13 (13.1%)
IVa 0 (0%) 4 (36.4%) 19 (32.2%) 23 (23.2%)
IVb 0 (0%) 0 (0%) 5 (8.5%) 5 (5.1%)
IVc 0 (0%) 0 (0%) 5 (8.5%) 5 (5.1%)
Unknown 10 (34.5%) 2 (18.2%) 10 (16.9%) 22 (22.2%)
Grade 1 9 (31.0%) 2 (18.2%) 13 (22.0%) 24 (24.2%)
2 7 (24.1%) 6 (54.6%) 22 (37.3%) 35 (35.4%)
3 13 (44.8%) 3 (27.3%) 21 (35.6%) 37 (37.4%)
Unknown 0 (0%) 0 (0%) 3 (5.1%) 3 (3.0%)
Therapy c Surgical 18 (62.1%) 8 (72.7%) 39 (66.1%) 65 (65.7%)
Surgery 11 (37.9%) 2 (18.2%) 16 (27.1%) 29 (29.3%)
Surgery + RT 4 (13.8%) 5 (45.5%) 14 (23.7%) 23 (23.2%)
Surgery + CRT 3 (10.314%) 1 (9.1%) 9 (15.3%) 13 (13.1%)
Non-surgical 1 (3.5%) 1 (9.1%) 6 (10.2%) 8 (8.1%)
Palliative 2 (6.9%) 0 (0%) 3 (5.1%) 5 (5.1%)
Unknown 8 (27.6%) 2 (18.2%) 11 (18.6%) 21 (21.2%)
p16 Positive 7 (24.1%) 2 (18.2%) 18 (30.5%) 27 (27.3%)
Negative 12 (41.4%) 7 (63.6%) 24 (40.7%) 43 (43.4%)
Unknown 10 (34.5%) 2 (18.2%) 17 (28.8%) 29 (29.3%)
a 26 patients had missing data for T/N classification of which 4 had recorded distant metastases and were thus classified as stage IVc
b total percentages are calculated against grand total
c RT- radio therapy, CRT–chemo and/or radiotherapy, non-surgical—any combination of chemo/radio therapy
https://doi.org/10.1371/journal.pone.0211577.t002
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Fig 2. Overall survival of OPSCC patients based on the gender, age group at the time of diagnosis, smoking
history and alcohol use.
https://doi.org/10.1371/journal.pone.0211577.g002
Fig 3. Overall survival of OPSCC patients based on HPV positivity, p16 data, and T and N classification.
https://doi.org/10.1371/journal.pone.0211577.g003
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stage) also significantly separated patients’ survival (P = 0.001). Cox proportional hazards
regression in univariate and multivariate analysis are presented in Tables 3 and 4.
Discussion
In this study, we performed HPV DNA and RNA analysis of oropharyngeal cancer patients
treated within a 15-year period. The overall results indicate that 29.3% of cancer cases had
active HPV E6 mRNA transcription and were thus likely HPV driven. The HPV DNA positiv-
ity, on the other hand, was shown in 40.4% patients, which is comparable with previous reports
[13,16]. Previous studies [11,28–30] have already concluded that HPV DNA presence is not
always sufficient to attribute cancer to HPV and that mRNA or combination of assays should
be used. Unexpectedly, the correlation between p16 and HPV data was low with correlation
coefficients r = -0.108 for comparison with HPV DNA and r = 0.146 for comparison with
RNA suggesting that p16 is not a suitable replacement for HPV testing in the current setting.
Some other studies have also shown that p16 testing might not be an accurate biomarker for
oropharyngeal cancers, since the presence of p16 has been detected in HPV–HNSCC [31].
However, literature also suggests that p16 positive, but HPV negative HNSCC, share some
common characteristics, like favorable prognosis, with HPV+ HNSCC [5,30,31]. However, in
our study there were also several HPV+ yet p16 negative tumors that negatively affected the
correlation. Such samples were also seen in the study of Jordan et al. [32]. However, recent
Cancer Genome Atlas project analysis [33] indicated that CDKN2A gene (encoding p16 pro-
tein) is often deleted or mutated in smoking related HNSCC cancers. Such deletions would
preclude p16 overexpression even if HPV is transcriptionally active.
Fig 4. Overall survival of OPSCC patients based type of therapy, on 7th edition and 8th edition of staging
guidelines and combined risk level (HPV status and T/N classification) based on those proposed by Ang et al.
[24].
https://doi.org/10.1371/journal.pone.0211577.g004
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This study encompass samples mostly from male patients with cancer in the oropharyngeal
region, particularly base of tongue and tonsil, which is consistent with previous reports
[13,34]. Those two regions also had the most HPV+ cases, which is in line with the literature
Table 3. Univariate proportional hazard regression of patient survival for tested variables.
Variable Factora N Relative risk 95% confidence interval P Overall model significance
Gender F 16 1 P = 0.207
M 65 1.5 0.7 to 2.9 0.229
Age continuous 81 1 0.9 to 1.1 0.063 P = 0.062
Age <45 6 P = 0.127
45–64 51 2.8 0.9 to 9.2 0.081
65+ 24 2.6 0.8 to 8.9 0.126
T 1–2 34 1 P = 0.038
3–4 29 1.9 1.1 to 3.5 0.017
Unknown 18 1.8 0.9 to 3.4 0.079
N 0–1 30 1 P = 0.006
2–3 33 2.4 1.4 to 4.3 0.003
Unknown 18 2.1 1.1 to 3.9 0.037
Stage 7th I-II 17 1 P = 0.009
III-IV 50 2.6 1.3 to 5.2 0.006
Unknown 14 2.6 1.1 to 6.1 0.031
Stage 8th I-II 26 1 P = 0.001
III-IV 41 2.9 1.6 to 5.4 0.001
Unknown 14 2.4 1.1 to 5.1 0.029
Grade 1 19 1 P = 0.876
2 29 1.1 0.6 to 2.3 0.619
3 31 1.1 0.6 to 2.2 0.711
Unknown 2 2.4 0.5 to 10.7 0.246
HPV overall no HPV 49 1 P = 0.893
inactive HPV 11 0.9 0.4 to 1.8 0.763
active HPV 21 1.1 0.6 to 1.9 0.776
HPV DNA no HPV 49 1 P = 0.964
HPV DNA+ 32 1.0 0.6 to 1.7 0.965
HPV RNA no HPV 60 1 P = 0.714
HPV RNA+ 21 1.1 0.6 to 1.9 0.712
p16 p16 negative 36 1 P = 0.569
p16 + 22 1.2 0.7 to 2.0 0.603
Unknown 23 0.8 0.4 to 1.5 0.510
Alcohol No alcohol 11 1 P = 0.075
Occasional use 18 2.3 0.8 to 6.4 0.103
Heavy use 8 4.0 1.3 to 12.3 0.015
Unknown 44 2.5 0.9 to 6.3 0.059
Smoking No smoking 8 1 P = 0.279
Former 9 2.7 0.7 to 10.3 0.138
Current 20 2.7 0.8 to 9.1 0.115
Unknown 44 2.7 0.8 to 8.7 0.099
aFactors reaching statistical significance are highlighted by bold font
https://doi.org/10.1371/journal.pone.0211577.t003
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[35] and cancers at those particular sites are the most responsible for the rising incidence of
HNSCC in many Western countries [12,36,37].
Surprisingly, there were no significant differences in patient or clinical parameters between
groups based on HPV RNA or only DNA or even p16 results. The overall 5-year survival was
relatively low (30.9%), however, this was influenced by the lack of disease specific mortality
data, which allows the calculation based only on all-cause mortality for the majority of patients.
The use of all-cause mortality might also be masking the effects of other variables, which, with
the exception of T and N stages (P = 0.041 and P = 0.022, respectively), failed to adequately
stratify patient risk of death on Kaplan-Myer analysis. However, the combined risk stratifica-
tion as proposed by Ang et al [27] originally combining HPV, smoking (not included in our
calculation) and TNM stage almost perfectly classified patients in low/intermediate and high
risk of death groups (Fig 4; P = 0.001). Similar results were obtained on univariate and multi-
variate Cox proportional hazards regression (Tables 3 and 4). Namely, only T and N classifica-
tions (and staging based on this variables) significantly affected survival with the N
classification significant in both univariate and multivariate models. However, HPV did not
confer significant survival benefit in either test.
The lack of impact of HPV or even p16 on survival was surprising; however, several factors
could be responsible. One of the major influences that could mask any positive HPV/p16
effects on survival is smoking and drinking history. Only 14% of patients never smoked and
13% never consumed alcohol with the majority still being an active smoker and at least moder-
ate drinker (Table 1). Smoking is still a significant problem in Croatia [38], with almost no
change in smoking prevalence seen for males in the 1994–2005 period with a slight decrease
from 34.1% to 33.8%. The more recent World Health Organization (WHO) report on smoking
prevalence [39] estimates an even greater male smoking prevalence in Croatia for year 2015 at
37.9% with the similar rate, around 24% for UK or USA. This, together with previous studies
that have shown that smoking can have the greatest effect on survival and even outweigh HPV
effect [40,41], most probably explains our findings. The hazardous effect of smoking on cancer
risk was shown for both HPV+ and HPV–HNSCC [42] even at low doses [43]. Furthermore,
the strong influence of smoking on cancer in Croatia is also demonstrated in a recent review
Table 4. Multivariate proportional hazard regression models for tested variables.
Variable Factora Multivariate model 1 (n = 63)overall model significance
P<0.001
Multivariate model 2 (n = 35)overall model significance
P = 0.005
Relativerisk 95% confidenceinterval P Relativerisk 95% confidenceinterval P
T 1–2 1 1
3–4 1.3 0.6 to 2.5 0.485 1.9 0.7 to 5.2 0.241
N 0–1 1 1
2–3 3.3 1.5 to 7.1 0.003 4.6 1.2 to 17.0 0.023
HPV overall no HPV 1 1
inactive HPV 2.3 1.0 to 5.0 0.043 3.3 0.9 to 11.5 0.069
active HPV 0.5 0.2 to 1.1 0.091 1.0 0.3 to 3.5 0.967
Alcohol No alcohol not included in model 1
Occasional use 1.4843 0.4 to 5.6 0.560
Heavy use 2.9149 0.7 to 13.2 0.166
Smoking No smoking not included in model 1
Former 1.7463 0.3 to 9.1 0.510
Current 0.8471 0.2 to 4.4 0.845
aFactors reaching statistical significance are highlighted by bold font
https://doi.org/10.1371/journal.pone.0211577.t004
HPV associated OPSCC survival
PLOS ONE | https://doi.org/10.1371/journal.pone.0211577 February 1, 2019 11 / 17
of lung cancer [44]. Therein, Croatia was among 20 countries with the highest incidence of
lung cancer in the world. Thus, Croatian patients are yet to benefit from smoking cessation
programs and past smoking history most likely influenced development of associated cancer
types. It was moderately surprising that smoking was not significantly affecting survival on
Cox regression analysis; however, it is likely that patients self-reported less smoking than they
actually did due to the recent social stigma associated with smoking and antismoking cam-
paign. The multivariate models also suffer from lack of data since only 35 patients had com-
plete information for analysis. Similarly, alcohol drinking is known to increase cancer risk [45]
and it is prominent in the Croatian population. The WHO report on alcohol consumption
[46] put Croatia among the top countries according to age standardized alcohol-attributable
malignant neoplasm death rates in 2016. Interestingly the univariate model indicated that
heavy drinking (and/or strong spirits use) significantly decreased survival (Table 3) indicating
that alcohol might represent even a higher health concern than smoking in Croatia.
Another factor potentially influencing our findings is that, surprisingly, there were no sig-
nificant differences between groups with regards to age at diagnosis in our study population,
which might also hint at a more classical etiology. Previous studies have shown that HPV
+ HNSCC primarily affects younger patients with higher socio-economic status and this par-
ticular group is the underlying cause for increasing incidence of HNSCC [5,34,47–49]. It
appears that in Croatia, and possibly elsewhere, societal and life style changes are lagging
behind more developed countries and not enough time has elapsed to shift the importance of
risk factors in HNSCC development from classical smoking and drinking to the new HPV
related risks. There appears to be no significant shift in incidence (particularly in younger
patients) or survival usually associated with HPV positivity. Interestingly, the study by Nygard
et al [49] showed that in Norway, there was a period (1981–1995) in which the survival of HPV
+ HNSCC was even worse than the HPV–HNSCC. However, in more recent years (1996–
2007) there was a dramatic shift in the survival of HPV+ patients. The median age of diagnosis
decreased from 63.2 to 59.8 years for HPV+ but remained unchanged at 66 for HPV–patients.
In our study, there was no observable difference in age at diagnosis between patient groups,
and there were no survival differences, thus, making the overall results comparable to the
1981–1995 period in Norway. This indicates that in our non-Western population additional,
classic, factors are somewhat more involved in HNSCC outcomes. On the other hand, some of
the “younger population” trends were recently shown to be changing in the Western popula-
tions as well [6,7]. However, data [8] also suggests that the prognostic advantage of HPV is
attenuated in older patients.
Current literature also suggests significant geographical variations of HPV involvement in
HNSCC. This was recently supported by a study [50] analyzing data from 4 multinational ran-
domized trials, which suggested geographic variability as being important for OPSCC. In the
study of Mehanna et al., HPV+ (DNA and p16 together) HNSCC seemed to be of less rele-
vance in Eastern Europe (6%) and Asia (2%) compared to more developed Western countries
(37%), where most of current literature derives from [50]. For comparison, in our study, there
were only 8 cases where both DNA, RNA and p16 were positive (7%) or 10 cases (8.7%) where
only DNA and p16 were positive, suggesting that the data is similar and HPV doesn’t play a
major role in HNSCC in this geographical region. Similar data is seen in other socio-economi-
cally alike populations as Spain [51], where HPV/p16 positive samples amount to 6% of
OPSCC cases and there was no significant survival improvement for HPV/p16 positive cases.
Data from geographically closer Italy suggests that HPV driven HNSCC there are also under-
represented compared to the rest of Western/Northern Europe. However, survival was posi-
tively affected in their HPV driven tumor patients [52], which might also be affected by
relatively greater economic development of North Italy region analyzed therein.
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Another recent study describes predictors of OPSCC survival in Europe [53]; the analysis
was based on 321 OPSCC subset with similar patient characteristics as ours. The study indi-
cated reduced hazard ratio of 0.59 for HPV serology positive patients, whereas, in our study
there were no significant differences in survival, which is most likely due to potential behavior
differences between Western and non-Western populations.
Our study had several limitations. The first limitation was due to the nature of FFPE sam-
ples where the nucleic acid quality is suboptimal, however, this was mitigated by the use of
PCR assays suitable both for DNA and RNA amplification from FFPE material. Furthermore,
internal control beta-actin amplifications were performed to assess material suitability before
HPV amplification. The second limitation was the retrospective nature of the study, where
proper documentation was not always available; sometimes detailed follow-up was impossible
because the patient visited other hospitals after initial treatment. Therefore, the medical rec-
ords were supplemented by data (if available) from the Croatian Cancer Registry that on a
national level collects relevant information on patient’s cancer irrespective of where the patient
was referred, and also contains survival data. The European multicenter study [53] also faced
data obstacles to a similar extent (22% missing cancer stage information herein; 16% in their
study). Finally, the third limitation was the relatively small size that correlates with the inci-
dence of oropharyngeal cancer in Croatia. However, to put our results in to context, the recent
meta-analysis by Albers et al [30] looking at the influence of HPV and p16 patterns on
HNSCC patient survival included 25 different studies of which the current study falls roughly
in the middle of regarding sample size.
Conclusions
In summary, this study provides the baseline relevant data for treatment of OPSCC patients in
Croatia. Eventual policy and treatment decisions in similar regions should take into account
the particularities of each population. Other factors like advanced stage, patient age or still
highly prevalent smoking and drinking in Croatia might be overshadowing the positive effect
of HPV seen in Western populations. Current data indicates that HPV, as a favorable prognos-
tic marker, should not be considered to outweigh other relevant factors in a particular popula-
tion until other socio-epidemiological changes evident in Western populations are also
observed.
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